Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aussie CRO Novotech Expands Asian Footprint With Indian ETI Joint Venture: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

The largest independent contract research organization in Australia, Sydney-based Novotech announced May 6 that it formed a joint venture with Bangalore-based ETI Klinical, which is part of the multinational Karle Group. With operations in Australia, New Zealand, the United States, India and South Korea, Novotech CEO Alek Safarian talked with PharmAsia News' Australia bureau about the joint venture and the company's plans to further expand its footprint in emerging markets in Asia.

You may also be interested in...



Australian CRO Novotech Expands Asian Footprint Into Southeast Asia

PERTH, Australia - Australia's largest independent contract research organization, Sydney-based Novotech, is expanding its operations into four new Asian markets and establishing a management hub in Kuala Lumpur, Malaysia

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel